MedTrace Logo

Sponsor Initiated Expanded Access Protocol, Intermediate-Size Patient Population

NCT04586062 · Status: AVAILABLE · Type: EXPANDED_ACCESS

Last updated 2023-10-05

No results posted yet for this study

Summary

The purpose of this protocol is to provide compassionate use of Kedrion Human Plasminogen Ophthalmologic Drops to an expanded population of patients diagnosed with ligneous conjunctivitis associated with type I Plasminogen deficiency until product licensure, and/or until a new clinical trial is available and the patients in treatment under Expanded Access are eligible to participate in the new trial.

Conditions

  • Ligneous Conjunctivitis

Interventions

DRUG

Plasminogen

Human Plasminogen

Sponsors & Collaborators

  • Kedrion S.p.A.

    lead INDUSTRY

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04586062 on ClinicalTrials.gov